Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Fiscal year ended December 31, 2001.
Status: Development stage company engaged in the research and development of synthetic blood plasma volume expanders, blood replacement solutions for hypothermic surgery, and organ preservation solutions.
Key Product: Hextend(R), a physiologically balanced blood plasma volume expander sold exclusively in the U.S. and Canada by Abbott Laboratories.
Key Financial Metrics
| Metric | 2001 | 2000 |
|---|---|---|
| Total Revenue | $151,917 | $52,492 |
| Net Loss | $(3,658,825) | $(4,925,024) |
| Loss Per Share (Basic/Diluted) | $(0.32) | $(0.44) |
| Cash and Cash Equivalents | $1,652,748 | $1,318,338 |
| Working Capital | $1,452,832 | $1,081,237 |
| Total Debt (Debentures) | $3,350,000 | $0 |
| Shareholders' Equity | $(99,094) | $1,317,735 |
Note: Revenue consists entirely of royalties from Hextend sales. The company has incurred cumulative losses of $30,770,238 since inception.
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenue increased 189% to $151,917 from $52,492, driven by a 760% increase in semi-annual Hextend sales volume from late 1999 to late 2001.
- Expense Reduction: Research and development expenses decreased 50% to $1.69 million from $3.36 million due to a cost-reduction program and reduced laboratory study expenses.
- Debt Financing: The company incurred $278,576 in interest expense in 2001 (none in 2000) following the issuance of $3.35 million in debentures in August 2001.
- Equity Position: Shareholders' equity turned negative to $(99,094) in 2001 from a positive $1.32 million in 2000, primarily due to the net loss for the year.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash ($1.65 million) and a new $300,000 line of credit (secured March 2002) are sufficient to operate through December 31, 2002. However, additional capital is required to commence clinical trials for PentaLyte and continue product development.
- Debt Covenants: The 2001 debentures restrict quarterly operating cash payments to $450,000 plus cash revenues until the debt is paid or $5 million in equity is raised. Dividends are prohibited until debt is repaid.
- Product Pipeline:
- Hextend: Sales are in a ramp-up phase; current monthly sales are estimated at nearly half the break-even point.
- PentaLyte: Phase I clinical trial completed; Phase II planned for hypovolemia treatment.
- HetaCool: In development for low-temperature surgery and organ preservation; animal trials show feasibility for blood replacement at near-freezing temperatures.
- Risks: Significant risks include the inability to raise additional capital, failure to obtain FDA approval for new products, competition from established plasma expanders (albumin, crystalloids), and reliance on Abbott Laboratories for marketing and manufacturing.
Investor Verification Checklist
- Cash Runway: Verify if the $1.65 million cash balance and $300,000 credit line are sufficient to meet the $450,000 quarterly operating cap imposed by debenture covenants.
- Abbott Sales Data: Confirm the trend of Hextend sales reported by Abbott, as BioTime's revenue recognition is delayed by 90 days and dependent on Abbott's reporting.
- Regulatory Milestones: Monitor the status of the Investigational New Drug (IND) application for PentaLyte and the regulatory approval for Hextend in Canada and Sweden.
- Dilution Risk: Assess the potential dilution from outstanding warrants (515,383 shares at $6.50) and options (485,701 shares) if the company raises equity to fund future trials.
- Debt Maturity: Note the $3.35 million debenture principal is due August 1, 2004, requiring refinancing or repayment well before that date given current cash flow constraints.